Security key
45720N103
Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share (INBX)
CUSIP: 45720N103
Q3 2024 13F Holders as of 30 Sep 2024
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Total 13F shares
- 8,897,409
- Total 13F value
- $139,328,871
- Share change
- -793,966
- Put/Call ratio
- 35%
- SEC-reported price per share
- $15.66
- Number of holders
- 95
- Value change
- -$10,813,194
- Number of buys
- 53
- Number of sells
- 29
- Shares outstanding
- 14,665,629
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2024
Institutions
95
Top holders
10
INBX full security history
Ownership snapshot
Full 13F holder table
Inhibrx Biosciences, Inc. SEC filings
Inhibrx Biosciences, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of INBX - Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Jon Faiz Kayyem
Disclosed value leader
VIKING GLOBAL INVESTORS LP
Comparable rows
2/15
Latest evidence
12 Sep 2024
13D/G
3/4/5
13F
Lead comparable stake: 7.9%
13 rows are not safely comparable across share classes.
13D/G row: Jon Faiz Kayyem
Showing 1-6 of 15 holder rows.
Quick read
Jon Faiz Kayyem leads the comparable SEC ownership view at 7.9%.
2 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Jon Faiz Kayyem's linked filing trail.
Comparable ownership
Top 2
Jon Faiz Kayyem
7.9%
Mark P. Lappe
6.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Jon Faiz Kayyem |
13D/G
|
7.9%
Reported 13D/G
· 03 Jun 2024
|
$13,765,571
1,149,046 shares
|
$0 | 03 Jun 2024 |
| Mark P. Lappe |
13D/G
Mark Lappe
|
6.4%
Reported 13D/G
· 12 Sep 2024
|
$11,086,448
925,413 shares
|
$0 | 12 Sep 2024 |
| Inhibrx, Inc. |
3/4/5
10%+ Owner
|
—
denominator unverified
|
—
1,157,926 shares
|
— | 29 May 2024 |
| VIKING GLOBAL INVESTORS LP |
13F
Company
|
—
denominator unverified
|
$25,331,780
1,787,705 shares
|
— | 30 Jun 2024 |
| PERCEPTIVE ADVISORS LLC |
13F
Company
|
—
denominator unverified
|
$15,077,248
1,064,026 shares
|
— | 30 Jun 2024 |
| BlackRock Finance, Inc. |
13F
Company
|
—
denominator unverified
|
$9,679,169
683,075 shares
|
— | 30 Jun 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
95
Shares
8,897,409
Rows available
95
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2024 vs Q2 2024 Across Filers
Q2 2024 holders
86
Q3 2024 holders
95
Holder diff
9
| Investor | Q2 2024 Shares | Q3 2024 Shares | Share Diff | Share Chg % | Q2 2024 value | Q3 2024 value | Value change | Value Chg % |
|---|